Business
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (G
About this update from Annexon, Inc.
[{"type":"image","alt":"Annexon Biosciences","displaySize":"","headline":null,"caption":"Annexon Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/578fc108e7e0712a28769323578aa13e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J35LGkHzjL3FW6lOBPAtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/578fc108e7e0712a28769323578aa13e","width":300,"height":99}},"lazy":false},{"type":"text","content":"Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors","length":196,"tagName":"p"},{"type":"text","content":"ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity","length":148,"tagName":"p"},{"type":"text","content":"Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026","length":124,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of Lloyd Clark, M.D., as senior vice president, ophthalmology strategy and innovation. Dr. Clark brings more than 25 years of experience as a practicing retina specialist with deep expertise in drug development, portfolio strategy and bringing novel therapies to market.","length":593,"tagName":"p"},{"type":"text","content":"Dry AMD with GA is a leading cause of blindness that affects more than eight million patients worldwide with no approved therapies targeting the preservation of vision. ANX007 is a non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye. ANX007 is the only investigational therapy in GA to show significant vision preservation on the endpoints of best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA), as well as significant preservation of central retinal photoreceptors necessary for visual acuity. In th...